Latest 8-K filings

Smith Douglas Homes announced second quarter 2026 results, showing a 25% increase in home closings and a 32% rise in net new home orders, but a substantial drop in pretax income due to inventory impairment charges.

Shift4 Payments announced robust Q2 2026 financial results, showcasing significant year-over-year growth in gross revenue and Adjusted EBITDA, alongside continued international expansion.

Core Natural Resources announced robust second quarter 2026 financial and operational results, highlighted by strong net income, adjusted EBITDA, and significant capital returns to stockholders.

Bentley Systems announced robust second-quarter 2026 financial results, showcasing significant year-over-year growth in total revenues, subscriptions revenues, and Annualized Recurring Revenues (ARR).

Resolute Holdings Management, Inc. reported a significant increase in net loss per share to $(1.53) for the second quarter of 2026, compared to $(0.07) in the prior year, while Non-GAAP Fee-Related Earnings per share rose to $0.69.

Iovance Biotherapeutics announced record second-quarter 2026 revenue of $99.3 million, a 66% year-over-year increase, alongside significant clinical and regulatory advancements for its TIL therapies.

Tecnoglass Holdings Inc. announced record second quarter 2026 revenues of $295.3 million, a 15.6% increase year-over-year, driven by strong performance in both residential and commercial segments, despite facing higher raw material costs and tariffs.

BlackSky Technology Inc. announced strong second quarter 2026 results, with total revenue surging 50% year-over-year to $33 million, driven by significant demand for its space-based intelligence and AI services.

Vital Farms announced new credit facilities totaling $185 million and reported a significant net loss for Q2 2026, impacted by industry-wide egg oversupply and pricing pressures.

Viridian Therapeutics announced strong second quarter 2026 results, highlighted by the FDA approval and launch of Lumvoa for thyroid eye disease and robust pipeline advancements.

Ligand Pharmaceuticals announced robust second-quarter 2026 financial results, highlighted by a 32% year-over-year increase in royalty revenue and the successful acquisition of XOMA Royalty.

Opus Genetics announced Q2 2026 financial results, highlighting progress in gene therapy programs for inherited retinal diseases, with key data expected soon and cash runway extending into 2029.

Korro Bio reported Q2 2026 results, highlighting progress on KRRO-121 and KRRO-111, receiving EMA Orphan Drug Designation, and maintaining a cash runway into late 2028.

Warner Bros. Discovery reported a 12% ex-FX revenue decline for Q2 2026, with net income plummeting 91%, though its Streaming segment saw 10% ex-FX revenue growth and a 63% increase in Adjusted EBITDA.

Monte Rosa Therapeutics reported strong Q2 2026 progress with key clinical trial activations and enrollment completions, alongside a robust cash runway extending into 2029, though net loss widened.

Evolent Health announced second quarter 2026 results, showcasing significant revenue growth and providing an optimistic 2027 outlook with projected revenue increases exceeding 25%.

Cartesian Therapeutics announced strong Q2 2026 financial results, highlighting progress in its Descartes-08 clinical trials and a strategic partnership extending cash runway into 2028.

GPGI, Inc. announced its second quarter 2026 financial results, reporting Pro Forma Adjusted Net Sales of $473.2 million, down 4% year-over-year, while reiterating its full-year 2026 outlook.

Nexstar Media Group announced record-breaking second quarter 2026 net revenue of $2.0 billion, driven by the TEGNA acquisition and strong advertising growth.

Unity Software Inc. announced its second quarter 2026 financial results, showcasing a 24% year-over-year revenue increase to $546 million and a significant improvement in profitability.

Advanced Drainage Systems (ADS) announced robust first-quarter fiscal 2027 financial results, showcasing significant year-over-year growth in net sales and Adjusted EBITDA, alongside a 11% increase in its quarterly cash dividend.

Cooper Standard announced second quarter 2026 results showing a 2.2% sales increase to $721.3 million, but a net loss of $18.8 million and a decrease in Adjusted EBITDA.

Lamar Advertising Company announced robust second quarter 2026 operating results, exceeding expectations and leading to an upward revision of its full-year financial guidance.

BKV Corporation reported solid Q2 2026 results, exceeding operational targets and advancing strategic priorities, including the launch of new carbon capture projects and strong upstream performance.

TIC Solutions announced robust second quarter 2026 revenue of $584.3 million and a 20% year-over-year increase in backlog, while reaffirming full-year financial outlook.

Amylyx Pharmaceuticals reported Q2 2026 financial results, highlighting the completion of patient visits for the pivotal Phase 3 LUCIDITY trial of avexitide, with topline data expected in late August or early September 2026.

Keurig Dr Pepper Inc. announced robust second quarter 2026 financial results, driven by significant growth in U.S. Refreshment Beverages and JDE Peets, while reaffirming its full-year 2026 outlook.

CPI Card Group Inc. announced robust second quarter 2026 financial results, including a 15% revenue increase to $149 million and a 294% surge in net income to $2 million, leading to raised revenue and free cash flow guidance for the full year.

D-Wave Quantum Inc. announced robust second quarter 2026 financial results, showcasing a substantial increase in bookings and significant advancements in its dual-platform quantum computing technology.

Foghorn Therapeutics announced its second quarter 2026 financial and corporate update, detailing progress in its oncology and immunology programs, a strong cash position, and advancing clinical trials.